CryoPort Collaborates With Advinus Therapeutics

LAKE FOREST, CA -- (MARKET WIRE) -- 11/19/08 -- CryoPort, Inc. (OTCBB: CYRX) today announced that it is collaborating with Advinus Therapeutics on commercial CryoPort Express(TM) shipments to India.

The collaboration has involved shipping frozen samples from two sites in the U.S. to Bangalore for analysis. Advinus is one of the leading R&D alliances and pharmaceutical research outsourcing companies in India, part of the Tata Group, one of India's largest and most respected business conglomerates.

Peter Berry, President and CEO of CryoPort, commented, "Advinus has provided important feedback concerning the application of the CryoPort Express(TM) System in India. As we start to expand shipments for customers throughout the subcontinent, the positive experience of companies involved with chemical analysis and drug development reinforce the value of our system."

To be added to the CryoPort Investor email list, please email edward@carpedminc.com with CYRX in the subject line.

About CryoPort, Inc.

CryoPort (www.cryoport.com) develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.

"SAFE HARBOR"

This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:
Stuart Fine
Carpe DM, Inc.
908-469-1788

Released November 19, 2008